Hyderabad, India-based Aurobindo Pharma announced that its wholly owned subsidiary Eugia Pharma Specialties, received a final approval from the U.S. Food & Drug Administration to manufacture and market Leuprolide Acetate Injection. Injectables This drug is used in palliative treatment of advance prostatic cancer. It had an estimated market size of $83...
India’s Eugia Pharma Gets USFDA Approval to Make and Market Prostate Cancer Drug
Hyderabad, India-headquartered Aurobindo Pharma announced that its wholly- owned subsidiary Eugia Pharma Specialties, received final approval from the U.S. Food & Drug Administration to manufacture and market Leuprolide Acetate injection, 14 mg/2.8 mL MDV (Kit). This drug is indicated for the palliative treatment of advanced prostate cancer. The product is...